Five of 27 patients with an aggressive and hard-to-treat form of breast cancer responded to treatment with Merck's checkpoint inhibitor Keytruda.
Beta-thalassemia patients no longer require blood transfusions following a single treatment with Bluebird's LentiGlobin gene therapy.
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
Agios and Celgene are accelerating development of AG-221 based on updated results from an early study showing strong and durable activity.
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
Checkpoint inhibitors can prime a patient's own immune system to kill certain types of blood cancer cells just like they do with solid tumors such as melanoma and lung cancer.
New Adcetris data are from a phase III study known AETHERA are being presented in full at the American Society of Hematology (ASH) annual meeting underway in San Francisco.
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.